UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

The New England journal of medicine, 2014-12, Vol.371 (23), p.2167-2177

2014

Link zum Volltext

Verfügbarkeit prüfen

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

The Lancet (British edition), 2005-04, Vol.365 (9468), p.1389-1397

2005

Link zum Volltext

Verfügbarkeit prüfen

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation

Cochrane database of systematic reviews, 2007-10 (4), p.CD005353

2007

Link zum Volltext

Verfügbarkeit prüfen

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

European heart journal, 2008-07, Vol.29 (14), p.1761-1771

2008

Link zum Volltext

Verfügbarkeit prüfen

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

The New England journal of medicine, 2021-03, Vol.384 (9), p.795-807

2021

Link zum Volltext

Verfügbarkeit prüfen

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

The New England journal of medicine, 2019-11, Vol.381 (19), p.1809-1819

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2019-11, Vol.394 (10212), p.1940-1948

2019

Link zum Volltext

Verfügbarkeit prüfen

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

The New England journal of medicine, 2018-10, Vol.379 (17), p.1599-1611

2018

Link zum Volltext

Verfügbarkeit prüfen

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Clinical pharmacokinetics, 2019-10, Vol.58 (10), p.1265-1279

2019

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.43-56

2019

Link zum Volltext

Verfügbarkeit prüfen

Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes

The New England journal of medicine, 2021-08, Vol.385 (9), p.815-825

2021

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

The New England journal of medicine, 2019-08, Vol.381 (5), p.432-443

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-11, Vol.326 (17), p.1703

2021

Link zum Volltext

Verfügbarkeit prüfen

Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience

Journal of thrombosis and haemostasis, 2020-06, Vol.18 (6), p.1320-1323

2020

Link zum Volltext

Verfügbarkeit prüfen

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

Cancer discovery, 2022-02, Vol.12 (2), p.402-415

2022

Link zum Volltext

Verfügbarkeit prüfen

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

The New England journal of medicine, 2019-04, Vol.380 (16), p.1509-1524

2019

Link zum Volltext

Verfügbarkeit prüfen

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

The New England journal of medicine, 2020-04, Vol.382 (17), p.1599-1607

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3401-3408

2015

Link zum Volltext

Verfügbarkeit prüfen

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

British journal of cancer, 2018-11, Vol.119 (10), p.1208-1214

2018

Link zum Volltext

Verfügbarkeit prüfen

Two Phase 3 Trials of Baricitinib for Alopecia Areata

The New England journal of medicine, 2022-05, Vol.386 (18), p.1687-1699

2022

Link zum Volltext

Verfügbarkeit prüfen

Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study

Blood, 2017-10, Vol.130 (15), p.1706-1712

2017

Link zum Volltext

Verfügbarkeit prüfen

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

The New England journal of medicine, 2019-07, Vol.381 (4), p.338-348

2019

Link zum Volltext

Verfügbarkeit prüfen

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

The New England journal of medicine, 2020-05, Vol.382 (19), p.1800-1810

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 4.637

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.150)
Mit Volltextzugriff
(3.377)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(4.148)
Science & Technology
(3.693)
Life Sciences & Biomedicine
(3.640)
Pyrazoles - Adverse Effects
(2.893)
Male
(2.312)
Female
(2.077)
Pyrazoles - Therapeutic Use
(1.781)
Middle Aged
(1.601)
Aged
(1.542)
Pyrazoles - Administration & Dosage
(1.221)
Adult
(1.219)
Celecoxib
(1.066)
Sulfonamides - Adverse Effects
(911)
Treatment Outcome
(873)
Pharmacology & Pharmacy
(781)
Animals
(759)
Oncology
(751)
Biological And Medical Sciences
(725)
Pyrazoles
(724)
Medical Sciences
(700)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The New England Journal Of Medicine
(103)
Blood
(65)
Clinical Cancer Research
(60)
British Journal Of Haematology
(56)
Leukemia & Lymphoma
(52)
Journal Of Nuclear Cardiology
(51)
The Lancet
(50)
American Journal Of Hematology
(39)
Mmw Fortschritte Der Medizin
(39)
Investigational New Drugs
(36)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Two Phase 3 Trials of Baricitinib for Alopecia Areata

Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

Suchergebnisse filtern